PUT - SPRINTER OPEN END - BIOGEN IDEC | Delayed Deutsche Boerse AG 14:04:44 2024-05-17 EDT | ||
| 18.16 EUR | -0.11% |
|
| Current month | -7.62% | ||
| 1 month | -16.07% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 18.16 | -0.11% |
| 24-05-16 | 18.18 | +3.53% |
| 24-05-15 | 17.56 | -5.79% |
| 24-05-14 | 18.64 | -0.64% |
| 24-05-13 | 18.76 | -1.16% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 02:04 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VQ8H82 |
| ISIN | DE000VQ8H822 |
| Date issued | 2021-06-09 |
| Strike | 424.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.47 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.14 € |
|---|---|
| Lowest since issue | 1.05 € |
| Spread | 0.03 € |
| Spread % | 0.16% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230
USD
Average target price
285.9
USD
Spread / Average Target
+24.29%
- Stock Market
- Certificates
- Certificat